Clinical studies evaluating BETAFERON


 

BETAFERON has been thoroughly and successfully studied in, and is therefore indicated for the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS) [1] .

 

BETAFERON in CIS: The BENEFIT study

BETAFERON in RRMS: The pivotal study

BETAFERON in SPMS

References

  • BETAFERON European Summary of Product Characteristics, October 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_en.pdf Return to content
Alt tag